Part 320 - Bioavailability and Bioequivalence

Part 320 sets the requirements for demonstrating bioavailability and bioequivalence of generic drug products, outlining study design, statistical analysis, and acceptance criteria. It guides sponsors in conducting comparative clinical pharmacology studies to ensure therapeutic equivalence with reference-listed drugs.